Acadia Pharmaceuticals (ACAD) PT Raised to $54 at Jefferies
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $29.58 -3.24%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 20 | New: 18
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 20 | New: 18
Join SI Premium – FREE
Jefferies analyst Chris Howerton raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $54.00 (from $53.00) while maintaining a Buy rating.
You May Also Be Interested In
- Revolution (RVMD) PT Raised to $260 at Oppenheimer
- Li Auto (LI) PT Lowered to $16 at US Tiger Securities
- EU approves Acadia's trofinetide for Rett syndrome treatment
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
